About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Periperal Blood Lymphocytes During Prostate RT | Clinical Trials | Clareo Health

Back to clinical trial search

WITHDRAWNNCT01899391

Periperal Blood Lymphocytes During Prostate RT

Right now it is not possible to predict which patients are going to react more to RT. Many things could affect patient's response to radiation. One of the factors is whether the person can repair dama...

Lead sponsor: University Health Network, Toronto•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Health Network, Toronto

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Intermediate-risk prostate cancer patients (T1/T2N0M0 with either GS \< 7 and PSA between 10-20 ng/ml or GS 7 and PSA less than 20 ng/ml).
•Planned for radical RT to the prostate with IMRT planning (79Gy/39fractions or 60 Gy/20 fractions).
•No contraindications to diagnostic CT scanning.
•Prostate volumes will be less than 80 cc to control the planning dose volume histogram (DVH) as much as possible in terms of rectal and bladder volumes.
•No known DNA repair disorders (e.g. family history of AT, BRCA1/2 or Li Fraumeni syndrome) or contraindications to radical pelvic RT.

Exclusion Criteria

•Inability to provide informed consent.
•Patient having contraindications to diagnostic CT scan.
•Patients who have unobtainable data regarding previous therapy and their clinical outcome.
•Patients should not have any diagnostic X-rays or CAT scans 2 weeks prior to their enrollment into the study.

Related studies

Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE)

NCT07580196 · Prostate Cancer

Selecting Hypoxic Tumours for Treatment Modification

NCT06787053 · Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer

RECRUITINGPhase 1/2

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT06616155 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more

DESTINY-PANTUMOUR04

NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more

Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

NCT07181122 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 15, 2013Terms

Trial snapshot

StatusWITHDRAWN

Phase—

Enrollment—

Start dateAug 2009

Last updatedJul 15, 2013

Condition

Prostate Cancer

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 15, 2013Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions